Repligen Corp (RGEN) Stock Price, Quote & News

Company Profile

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale co...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 781 250 0111

Fax: 781 250 0115

Website: www.repligen.com

Address:

Building 1, Suite 100 41 Seyon Street, Waltham, United States

Estimize Jul. 14 at 11:00 AM

Wall St is expecting 0.39 EPS for $RGEN Q2 [Reporting 08/05 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co

0 · Reply

gargoyl Jul. 9 at 4:55 PM

$BLRX 👀 Beast mode 🦍 on deck Momentum is 👂 hear PDAC Let’s treat cancer ♋️ $BMY $RGEN $PFE

0 · Reply

JarvisFlow Jul. 8 at 1:05 PM

Evercore ISI Group updates rating for Repligen ( $RGEN ) to In-Line, target set at 140 → 130.

0 · Reply

Estimize Jul. 8 at 11:00 AM

Wall St is expecting 0.39 EPS for $RGEN Q2 [Reporting 08/05 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co

0 · Reply

Estimize Jul. 7 at 11:00 AM

Wall St is expecting 0.39 EPS for $RGEN Q2 [Reporting 08/05 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co

0 · Reply

GoldenTradesCapital Jul. 1 at 11:32 AM

DID YOU KNOW… $RGEN MAKES EQUIPMENT FOR PFIZER & MODERNA? 💉 Repligen is a major supplier of bioprocessing equipment used in mRNA vaccine production — recurring revenue from Big Pharma. Follow us for more behind-the-scenes leaders 🔱

0 · Reply

GoldenTradesCapital Jun. 30 at 7:38 AM

STOCK RECOMMENDATION: $RGEN – QUIET LEADER IN BIOPROCESSING 🧪 Repligen supplies the equipment used by top biotech firms to manufacture therapies. High margins, solid growth, and low visibility make this a rare find. For more smart picks like this, follow us 🔱

0 · Reply

StockHunter75 Jun. 25 at 3:17 PM

$RGEN adding the dips

0 · Reply

Estimize Jun. 23 at 9:03 PM

Wall St is expecting 0.39 EPS for $RGEN Q2 [Reporting 08/05 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co

0 · Reply

StockHunter75 Jun. 20 at 3:04 PM

$RGEN buy at market large, don't let them see you coming.

0 · Reply

Repligen to Report Second Quarter 2025 Financial Results

Jun 16, 2025, 8:00 AM EDT - 4 weeks ago

908 Devices Appoints Christopher D. Brown to its Board of Directors

MASS

May 27, 2025, 7:30 AM EDT - 7 weeks ago

Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report

May 7, 2025, 7:30 AM EDT - 2 months ago

Repligen Corporation to Present at Upcoming May Investor Conferences

Apr 29, 2025, 12:58 PM EDT - 2 months ago

Repligen Corporation (RGEN) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 7:30 AM EDT - 2 months ago

Repligen Reports First Quarter 2025 Financial Results

Apr 8, 2025, 7:30 AM EDT - 3 months ago

Repligen Appoints Jacob Johnson As Vice President Investor Relations

Mar 20, 2025, 7:52 AM EDT - 4 months ago

Repligen: Ongoing Bioprocessing Market Recovery

Mar 4, 2025, 1:26 PM EST - 4 months ago

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

MASS

Mar 4, 2025, 7:30 AM EST - 4 months ago

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

MASS

Feb 20, 2025, 2:53 PM EST - 5 months ago

Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 2:00 PM EST - 5 months ago

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

Feb 11, 2025, 7:30 AM EST - 5 months ago

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

Jan 7, 2025, 7:30 AM EST - 6 months ago

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 7:30 AM EST - 6 months ago

Repligen Launches the CTech™ SoloVPE® PLUS System

Dec 16, 2024, 8:11 AM EST - 7 months ago

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

BLFS

Dec 12, 2024, 7:30 AM EST - 7 months ago

Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report

Dec 9, 2024, 7:30 AM EST - 7 months ago

Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

Nov 12, 2024, 3:07 PM EST - 8 months ago

Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 1:19 PM EST - 8 months ago

Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth

Nov 12, 2024, 6:36 AM EST - 8 months ago

Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects

Nov 5, 2024, 7:30 AM EST - 9 months ago

Repligen Corporation to Present at Upcoming Investor Conferences

Oct 14, 2024, 11:15 AM EDT - 9 months ago

Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More

Sep 24, 2024, 7:30 AM EDT - 10 months ago

Repligen Opens Training & Innovation Center to Elevate Customer Experience

Aug 23, 2024, 7:30 AM EDT - 11 months ago

Repligen Corporation to Present at Wells Fargo Healthcare Conference

Aug 16, 2024, 11:46 AM EDT - 11 months ago

Exclusive: Repligen in bid for reagent vendor Maravai, sources say

MRVI

Jul 31, 2024, 2:50 PM EDT - 1 year ago

These Analysts Revise Their Forecasts On Repligen Following Q2 Results

Jul 30, 2024, 3:03 PM EDT - 1 year ago

Repligen Corporation (RGEN) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 12:01 PM EDT - 1 year ago

Repligen Lowers Guidance On China Weakness, Analyst Expects

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Repligen Reports Second Quarter 2024 Financial Results

Jul 29, 2024, 4:00 PM EDT - 1 year ago

Repligen Announces Agreement to Acquire Chromatography Innovator Tantti

Jul 16, 2024, 7:30 AM EDT - 1 year ago

Repligen to Report Second Quarter 2024 Financial Results

Jun 26, 2024, 8:44 AM EDT - 1 year ago

This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

HOOD PAGS UHS X

Jun 21, 2024, 8:22 AM EDT - 1 year ago

Top 3 Health Care Stocks That Could Blast Off In June

ENOV PEN

Jun 13, 2024, 7:00 AM EDT - 1 year ago

Repligen Announces CEO Transition Plan

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing

May 22, 2024, 7:30 AM EDT - 1 year ago

Repligen Corporation to Present at Upcoming June Investor Conferences

May 1, 2024, 7:30 AM EDT - 1 year ago

Repligen Reports First Quarter 2024 Financial Results

Apr 17, 2024, 7:30 AM EDT - 1 year ago

Repligen to Report First Quarter 2024 Financial Results

Mar 19, 2024, 7:30 AM EDT - 1 year ago

Repligen Appoints Maggie A. Pax to Board of Directors

Feb 21, 2024, 2:35 PM EST - 1 year ago

Repligen Corporation (RGEN) Q4 2023 Earnings Call Transcript

Feb 21, 2024, 7:30 AM EST - 1 year ago

Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 7, 2024, 7:30 AM EST - 1 year ago

Repligen to Report Fourth Quarter and Full Year 2023 Financial Results

Dec 19, 2023, 7:30 AM EST - 1 year ago

Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 7, 2023, 7:30 AM EST - 1 year ago

Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements

Nov 14, 2023, 2:01 PM EST - 1 year ago

UPDATE – Repligen Announces Publication of the Company's 2022 Sustainability Report

Nov 14, 2023, 7:30 AM EST - 1 year ago

Repligen Announces Publication of the Company's 2022 Sustainability Report

Nov 2, 2023, 7:30 AM EDT - 1 year ago

Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device

Oct 31, 2023, 1:16 PM EDT - 1 year ago

Repligen Corporation (RGEN) Q3 2023 Earnings Call Transcript

Oct 31, 2023, 7:30 AM EDT - 1 year ago

Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

Estimize Jul. 14 at 11:00 AM

Wall St is expecting 0.39 EPS for $RGEN Q2 [Reporting 08/05 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co

0 · Reply

gargoyl Jul. 9 at 4:55 PM

$BLRX 👀 Beast mode 🦍 on deck Momentum is 👂 hear PDAC Let’s treat cancer ♋️ $BMY $RGEN $PFE

0 · Reply

JarvisFlow Jul. 8 at 1:05 PM

Evercore ISI Group updates rating for Repligen ( $RGEN ) to In-Line, target set at 140 → 130.

0 · Reply

Estimize Jul. 8 at 11:00 AM

Wall St is expecting 0.39 EPS for $RGEN Q2 [Reporting 08/05 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co

0 · Reply

Estimize Jul. 7 at 11:00 AM

Wall St is expecting 0.39 EPS for $RGEN Q2 [Reporting 08/05 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co

0 · Reply

GoldenTradesCapital Jul. 1 at 11:32 AM

0 · Reply

GoldenTradesCapital Jun. 30 at 7:38 AM

0 · Reply

StockHunter75 Jun. 25 at 3:17 PM

$RGEN adding the dips

0 · Reply

Estimize Jun. 23 at 9:03 PM

Wall St is expecting 0.39 EPS for $RGEN Q2 [Reporting 08/05 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co

0 · Reply

StockHunter75 Jun. 20 at 3:04 PM

$RGEN buy at market large, don't let them see you coming.

0 · Reply

StockHunter75 Jun. 20 at 3:03 PM

$RGEN load up time to burn some shorts.

0 · Reply

Estimize Jun. 17 at 3:00 PM

Wall St is expecting 0.40 EPS for $RGEN Q2 [Reporting 08/05 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co

0 · Reply

StockHunter75 Jun. 11 at 2:40 PM

$RGEN Bullish.

0 · Reply

CAN_2409 May. 29 at 12:19 AM

CADL Who will it be? .... $MRK $GSK $RGEN $NVS $PFE ? This would be the first new treatment for localized prostate cancer in over 20 years, Candel Therapeutics said in its news release. The company estimates this is a $10 billion-plus market in the U.S. alone!

0 · Reply

CAN_2409 May. 22 at 6:45 PM

$CADL yes I agree since the 2020 covid they $RGEN do need something new and better! Now they own a large DNA testing company 23andme they could help millions of people before they even get deadly cancers!!! Good call thanks Dog! Good Dog!!!

0 · Reply

eWhispers May. 10 at 1:03 PM

Every single Biotech stock in $BBH is lagging the S&P 500 $SPY since reporting earnings... FYI. https://www.earningswhispers.com/wrs $MRNA $BNTX $RGEN

1 · Reply

JarvisFlow May. 5 at 11:00 AM

HC Wainwright & Co. has adjusted their stance on Repligen ( $RGEN ), setting the rating to Buy with a target price of 180.

0 · Reply

ZacksResearch Apr. 30 at 1:40 PM

"$RGEN beat earnings & raised revenue outlook — but trimmed EPS? 🤔 📈 Q1 EPS of $0.39 tops $0.35 est — up from $0.30 YoY 💰 Revenue up 10% YoY to $169M, with 14% organic non-COVID growth 🧪 All 4 franchises posted double-digit order growth ⚙️ Gross margin up 450 bps to 53.7% 🔧 But 2025 EPS guide slightly cut after acquiring 908 Devices' biz Strong execution + solid order flow, but CDMO sales worth watching. In-depth research here 👉 https://www.zacks.com/commentary/2458760/repligens-q1-earnings-beat-estimates-revenues-surge-yy?cid=sm-stocktwits-2-2458760-body&ADID=SYND_STOCKTWITS_TWEET_2_2458760_BODY

0 · Reply

JarvisFlow Apr. 29 at 10:00 PM

JP Morgan has adjusted their stance on Repligen ( $RGEN ), setting the rating to Overweight with a target price of 200 → 190.

0 · Reply

Ironcladeee Apr. 29 at 1:50 PM

$RGEN one to watch

0 · Reply

TradingEtcetera Apr. 29 at 8:00 AM

🟢 RISK ON: Could these Non S&P 500 before market open earnings announcers be your BIGGEST GAINERS TODAY? I just could not wait to get started w/ my readjusted Swing Trading Earnings Plays (NO SHORTS). Will be posting 1st here. X (Twitter) will ONLY get updates + outcomes. Quick analysis + entries + exits now live here. 🔮 Heres the game plan + position risk size to be bought as soon as the extended session resumes at 4AM EST (1x Bet = 1% of balance): $THC Bet x3 Tenet Healthcare $SFD Bet x2 Smithfield Foods ~ Largest US pork processor IPOedin March. $RGEN Bet x1 Repligen ~ tread carefully; take profit quickly. $SOFI Bet x2 SoFi Technologies ~ not for the faint of heart; rollercoaster no doubt. No analysis on these as it's well past midnight here in Silicon Valley. Already picked after market close candidates for your PNL boosting pleasure later. Follow for more. Lets Eat! 🥩

0 · Reply

JarvisFlow Apr. 16 at 5:23 PM

Canaccord Genuity has adjusted their stance on Repligen ( $RGEN ), setting the rating to Hold with a target price of 170 → 150.

0 · Reply

Market Cap	6.73B
Revenue (ttm)	634.44M
Net Income (ttm)	-25.51M
EPS (ttm)	N/A
PE Ratio	74.28
Forward PE	70.43
Profit Margin	-4.02%
Debt to Equity Ratio	0.00

Volume	582,500
Avg Vol	743,436
Day's Range	N/A - N/A
Shares Out	56.18M
Stochastic %K	37%
Beta	1.11
Analysts	Strong Sell
Price Target	$180.88